3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
48
Lung Neoplasms
24
Carcinoma, Hepatocellular
24
Small Cell Lung Carcinoma
16
Urinary Bladder Neoplasms
12
Cholangiocarcinoma
12
Breast Neoplasms
10
Liver Neoplasms
9
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Pancreatic Neoplasms
7
Carcinoma
6
Endometrial Neoplasms
5
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Interventions
pembrolizumab
53
Paclitaxel
20
Cisplatin
15
Carboplatin
15
lenvatinib
10
Docetaxel
9
Saline Solution
7
Capecitabine
7
Pemetrexed
6
Oxaliplatin
6
Gemcitabine
6
Fluorouracil
6
Leucovorin
5
Albumin-Bound Paclitaxel
5
olaparib
4
belzutifan
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
patritumab deruxtecan
3
Glucose
3
Acetaminophen
3
liposomal doxorubicin
2
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Doxorubicin
2
Dexamethasone
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
durvalumab
×
90 days
×
Clear all
NCT04380636
2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
870 enrolled